SCHEMBL3084874

SCHEMBL3084874

[CH2]CCCCN1CCNCC1CC=C

nearest known ligand 0.37

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6665390 0.86 TAAR1 (0.41) TAAR1
SCHEMBL11786314 0.81 MITF (0.30) TAAR1
SCHEMBL3366367 0.78 CHRM2 (0.31)
SCHEMBL28329390 0.77 CHRNB2 (0.33) TAAR1
Ammonia Solution, Strong SCHEMBL5794126 0.77 CHRM2 (0.30)
Ammonia Solution, Strong SCHEMBL11786318 0.76 CHRNB2 (0.33) TAAR1
SCHEMBL294355 0.75 TAAR1 (0.47) TAAR1
SCHEMBL5013933 0.74
SCHEMBL11220405 0.73 CHRNB2 (0.32)
SCHEMBL27862434 0.72 TAAR1 (0.47) TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7786129-B2 Piperazine derivatives of dialkyl oxindoles EGIS GYOGYSZERGYAR NYRT (HU) 2010-08-31 US disclosed
EP-1776339-B1 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2009-07-01 EP disclosed
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles EGIS GYOGYSZERGYAR RT. (HU) 2007-10-04 US disclosed
EP-1776339-A2 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS Gyógyszergyár Nyrt (HU) 2007-04-25 EP disclosed
WO-2005109987-A9 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYOGYSZERGYAR NYRT (HU) 2007-03-29 WO disclosed
WO-2005109987-A2 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS EGIS GYÓGYSZERGYÁR NYRT. (HU) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232619-A1 Piperazine Derivatives of Dialkyl Oxindoles TPH2, DRD3, CNR2 TAAR1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.